Certa Therapeutics
Melbourne, Australia· Est.
Australian precision‑medicine biotech targeting fibrosis through GPR68 inhibition.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian precision‑medicine biotech targeting fibrosis through GPR68 inhibition.
FibrosisNephrology
Technology Platform
Selective oral small‑molecule antagonists of the GPR68 G‑protein‑coupled receptor, a master regulator of fibrosis.
Opportunities
Successful Phase III data for asengeprast could unlock orphan‑drug markets in systemic sclerosis and enable rapid expansion into other fibrotic indications.
Risk Factors
Clinical trial failure, safety concerns of chronic GPR68 inhibition, and competition from alternative anti‑fibrotic approaches.
Competitive Landscape
Few companies target GPR68; Certa’s differentiated upstream mechanism and oral delivery set it apart from larger firms pursuing downstream fibrosis pathways.